NEW YORK – Cardiff Oncology on Tuesday said it has completed enrolling patients with advanced RAS-mutated colorectal cancer in a Phase II trial testing the activity of its PLK1 inhibitor onvansertib ...

Ayrmid has not obtained the necessary financing to support its unsolicited, non-binding written proposal to purchase the company, Bluebird said.

Databricks will contribute data engineering and AI expertise to support the development of Tevogen's PredicTcell technology.